These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8237826)

  • 21. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
    MacNeil DJ
    Am J Cardiol; 1997 Oct; 80(8A):90G-98G. PubMed ID: 9354416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents.
    Singh BN
    Am J Cardiol; 1993 Aug; 72(4):8A-18A. PubMed ID: 8346731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):3A-11A; discussion 35A-36A. PubMed ID: 2403733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the ESVEM trial for use of antiarrhythmic drugs that prolong cardiac repolarization.
    Mason JW
    Am J Cardiol; 1993 Nov; 72(16):59F-61F. PubMed ID: 8237831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ischemic disorders of cardiac rhythm: effects of the autonomic nervous system on electrophysiologic findings and pharmacotherapy].
    Gülker H; Thale J
    Z Kardiol; 1986; 75 Suppl 5():15-34. PubMed ID: 3825228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm.
    Singh BN
    Am J Cardiol; 1998 Mar; 81(6A):3D-13D. PubMed ID: 9537217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The pro-arrhythmia effects of anti-arrhythmia agents--theoretical and clinical aspects].
    Steinbeck G
    Z Kardiol; 1992; 81 Suppl 4():139-43. PubMed ID: 1290290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha D
    Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential.
    Nair LA; Grant AO
    Cardiovasc Drugs Ther; 1997 Apr; 11(2):149-67. PubMed ID: 9140692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiarrhythmic agents and proarrhythmia.
    Chaudhry GM; Haffajee CI
    Crit Care Med; 2000 Oct; 28(10 Suppl):N158-64. PubMed ID: 11055685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of antiarrhythmic drugs.
    Lüderitz B; Mletzko R; Jung W; Manz M
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S48-52. PubMed ID: 1723119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanding indications for the use of Class III agents in patients at high risk for sudden death.
    Singh BN
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):887-900. PubMed ID: 8548110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed ventricular repolarization as an anti-arrhythmic principle.
    Vaughan Williams EM
    Eur Heart J; 1985 Nov; 6 Suppl D():145-9. PubMed ID: 2417849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
    Borggrefe M; Haverkamp W; Shenasa M; Hindricks G; Breithardt G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S32-40. PubMed ID: 1279307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions between implantable cardioverter-defibrillators and class III agents.
    Movsowitz C; Marchlinski FE
    Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.